Rahlyn Gossen (Founder, Revise · 15+ years in clinical trials) — Veeva's PBC conversion via Peter Gassner × Eric Ries: 'success is likely because of, not in spite of, adherence to values'

Rahlyn Gossen — Founder of Revise (site communication for tough clinical trials), 15+ years in the industry — publishes a clinical-trial-industry framing of Veeva's PBC conversion built around the Peter Gassner × Eric Ries interview from earlier this week. Uses Veeva ('perhaps the most profitable vertical SaaS ever') as the counter-example to profit-extraction playbooks she's watched come and go in her space. Positions the Gassner interview as ideal for Ries's Incorruptible thesis.

“Veeva's success is likely because of, not in spite of, adherence to values that are about more than money. And that lesson is what makes Gassner an ideal interview for Ries, who is promoting his new book Incorruptible” — Rahlyn Gossen on LinkedIn